Retina Research Clinical Trials

The Retina Institute is committed to developing solutions and treatment plans for individuals with sight-threatening diseases and vision problems. Their partnership with Acuity Eye Group allows us to extend these innovative treatments to the patients in our communities.


Past Clinical Trials

  • A Pilot Study to Evaluate Suprachoroidal XXXXX Therapy for Advanced Exudative Age-Related Macular Degeneration

  • A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of XXXXX plus XXXXX versus XXXXX plus Placebo in Patients with Sub-Foveal Choroidal Neovascn

  • Open-Label Dose Escalation Study of XXXXXX (Stratum I) Combined with a Prospective, Randomized, Double-Masked, Multicenter, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of XXXXXX Alone and in Combination with Ranibizumab versus Ranibizumab Alone in Diabetic Macular Edema (Matisse Study).

  • A Phase 2, Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of XXXXXX in Adult Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).

  • A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal XXXXX in Subjects with Neovascular Age-Related Macular Degeneration

  • An Open-Label, Long-Term, Safety and Tolerability Extension Study of Intravitreal XXXXX in Neovascular Age-Related Macular Degeneration

  • A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment- Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg XXXXX Administered Monthly or on an As-Needed Basis (prn) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

  • A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of XXXXX in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

  • A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection- Controlled Study of the Efficacy and Safety of XXXXX Injections in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus

  • A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of XXXXX in Patients with Diabetic Macular Edema (DME)

  • A Randomized, Single-Masked, Long-Term, Safety, and Tolerability Study of Intravitreal XXXXX in Subjects with Neovascular Age-Related Macular Degeneration

  • Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of XXXXX in Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) who Have Completed a XXXXX- Sponsored XXXXX Study

  • A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of XXXXX in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy

  • A Pilot Study to Evaluate a Combination Drug Therapy of XXXXX, XXXXX & XXXXX for Advanced Exudative Age-Related Macular Degeneration

  • XXXXX for Edema of the Macula in Diabetes: A Phase 2 Study

  • A Phase I Open-Label, Dose Escalation Trial of XXXXX Delivered by a Single Intravitreal Injection to Patients with Choroidal Neovascularization (CNV) Secondary to Exudative Age-Reularization Secondary to Age-Related Macular Degeneration

  • A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of XXXXX in Patients with Neovascular Age-Related Macular Degeneration

  • A 24-Month Randomized, Double-Masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of XXXXX Photodynamic Therapy Administered in Conjunction with XXXXX versus XXXXX Monotherapy in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

  • A Phase 3, Randomized, Double-Masked, Parallel-Assignment Study of Intravitreal XXXXX, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of XXXXX, Compared with XXXXX Monothereapy Every 4 weeks in Patients with AMD

  • A Randomized, Prospective, Active Controlled Study of the XXXXX for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age- Related Macular Degeneration

  • A 12-month Randomized, Double-Masked, Controlled, Multicenter, Phase IIIB Study assessing Safety and Efficacy of XXXXX Photodynamic Therapy administered in Conjunction with XXXXX versus XXXXX monotherapy in patients with subfoveal Choroidal Neovascularization secondary to Age-related Macular Degeneration CNV Secondary to AMD Treated with XXXXX

  • A Phase III, Multicenter, Randomized, Sham Injection – Controlled Study of the Efficacy and Safety of XXXXX Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)

  • A Phase III, Multicenter, Randomized, Sham Injection – Controlled Study of the Efficacy and Safety of XXXXX Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion.

  • A Phase 2, randomized, active-controlled, double-masked, multicenter study to assess the safety and efficacy of daily subcutaneous XXXX administered for 3 months, as monotherapy or adjunctive to ranibizumab, in subjects with diabetic Macular Edema

  • Randomized, double-masked, vehicle controlled, clinical evaluation to assess the safety and efficacy of nepafenac ophthalmic suspension, 0.3% for improvement in clinical outcomes among diabetic subjects following Cataract surgery

  • afety and Efficacy Study of XXXXXX versus XXXXXX for the Treatment of Exudative Age-Related Macular Degeneration.

  • A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of XXXXXX in Patients with Diabetic Macular Edema.

  • A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of XXXXXX versus XXXXXX in Subjects with Exudative Age-Related Macular Degeneration